List view / Grid view
16 February 2016 | By Victoria White
As part of the I-O RPM programme, Bristol-Myers Squibb and Dana-Farber Cancer Institute will conduct a range of early phase clinical studies...
3 February 2016 | By Victoria White
The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
26 January 2016 | By Victoria White
The three-year collaboration agreement provides a framework for MD Anderson and AbbVie to efficiently choose and carry out preclinical and clinical studies evaluating new ideas in immuno-oncology...
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
13 January 2016 | By Oxford Global
Ahead of the Advances in Immuno-oncology Congress, we spoke to Elaine Pinheiro, Principal Scientist at MSD about her group’s work and where the industry is moving at the moment...
11 January 2016 | By Victoria White
The agreement gives Novartis access to four preclinical programmes that target regulatory T-cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment...
5 January 2016 | By Victoria White
NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumours, in combination with radiotherapy...
24 November 2015 | By Victoria White
The companies have said they will focus is on immuno-oncology, one of the hottest and most dynamic areas in biotechnology...
17 November 2015 | By Victoria White
Antibodies against TIGIT could improve the function of the DNAM-1 protein, thereby improving the ability of natural killer cells to destroy tumour cells...
25 September 2015 | By Victoria White
Bristol-Myers Squibb and Moffitt will conduct a range of early phase clinical studies, including clinical investigations by young investigators to strengthen their development as clinical research scientists...
1 September 2015 | By Charlotte Batchelor
Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology...
6 August 2015 | By Victoria White
AstraZeneca and Heptares Therapeutics have entered into a licensing agreement to develop A2A receptor-blocking compounds as cancer immunotherapies...
28 July 2015 | By Victoria White
Regeneron and Sanofi have entered into a new global collaboration to discover, develop and commercialise new antibody cancer treatments in immuno-oncology...
Immune checkpoint inhibitory antibodies have provided a great conceptual change in the field of immune-oncology. Rather than targeting the tumour directly, these novel drugs are aimed at preventing the interactions between the tumour and the immune system, which the cancer exploits to evade immune recognition...
